NEW YORK (GenomeWeb) – Some six months after establishing itself as an independent entity, Olink Proteomics is planning a large expansion of its protein biomarker offerings and exploring the possibility of developing proprietary biomarker content.

The company aims by the end of the year to more than double its current assay offerings, CEO Jon Heimer told GenomeWeb this week. At the same time, it is "dipping its toes" into in-house biomarker development, he added.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

A trial upgrade to 360Dx Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try 360Dx Premium now.

Already a 360Dx Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.